Clinical trial
A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
NCT00406354 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- January 31, 2009
- Enrollment
- 181 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
attention deficit hyperactivity disorder, oppositional defiant disorder